Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CDNA 
CareDx Inc (CDNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: CDNA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $29.29
Year Target Price $29.29
| 4 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.07B USD | Price to earnings Ratio 17.17 | 1Y Target Price 29.29 |
Price to earnings Ratio 17.17 | 1Y Target Price 29.29 | ||
Volume (30-day avg) - | Beta 2.18 | 52 Weeks Range 14.09 - 34.84 | Updated Date 06/29/2025 |
52 Weeks Range 14.09 - 34.84 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 17.92% | Operating Margin (TTM) -9.46% |
Management Effectiveness
Return on Assets (TTM) -5.2% | Return on Equity (TTM) 19.54% |
Valuation
Trailing PE 17.17 | Forward PE - | Enterprise Value 869540151 | Price to Sales(TTM) 3.09 |
Enterprise Value 869540151 | Price to Sales(TTM) 3.09 | ||
Enterprise Value to Revenue 2.51 | Enterprise Value to EBITDA -2.82 | Shares Outstanding 55680500 | Shares Floating 54447782 |
Shares Outstanding 55680500 | Shares Floating 54447782 | ||
Percent Insiders 3.22 | Percent Institutions 99.39 |
Analyst Ratings
Rating 4.12 | Target Price 29.29 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CareDx Inc
Company Overview
History and Background
CareDx, Inc. was founded in 1998. It is a molecular diagnostics company focused on the development and commercialization of non-invasive surveillance solutions for transplant recipients. It has evolved from a focus on heart transplant diagnostics to a broader range of transplant areas, including kidney and other organ transplants.
Core Business Areas
- Transplant Monitoring Solutions: CareDx offers a range of molecular diagnostics solutions for transplant recipients. These solutions help physicians monitor the health of the transplanted organ and detect potential rejection episodes early.
- Digital Healthcare Solutions: CareDx provides digital healthcare solutions for transplant patients and clinicians, including tools for remote monitoring and patient management.
Leadership and Structure
The leadership team consists of individuals with expertise in diagnostics, biotechnology, and healthcare. The company has a board of directors overseeing the management team. CEO is currently Darvesh Patel
Top Products and Market Share
Key Offerings
- AlloSure: AlloSure is a donor-derived cell-free DNA (dd-cfDNA) test used to monitor kidney transplant recipients for rejection. Competitors include Natera (Prospera), Thermo Fisher Scientific (One Lambda). CareDx has significant market share in kidney transplant monitoring, estimated around 60% of the addressable market in the US.
- AlloMap: AlloMap is a gene expression test used to monitor heart transplant recipients for rejection. Competitors include traditional biopsy and other clinical assessments.
- RemoTraC: A home blood sample collection and shipping kit designed to improve the patient experience and increase adherence to surveillance testing.
Market Dynamics
Industry Overview
The transplant diagnostics industry is growing due to the increasing number of transplants performed each year and the need for improved monitoring tools to prevent rejection. The industry is moving towards less invasive testing methods.
Positioning
CareDx is positioned as a leading provider of non-invasive transplant monitoring solutions, with a strong focus on innovation and patient care. They have a first-mover advantage in some segments, but are facing increasing competition.
Total Addressable Market (TAM)
The estimated TAM for transplant monitoring is several billion USD. CareDx is positioned to capture a significant portion of this market through its comprehensive product portfolio.
Upturn SWOT Analysis
Strengths
- Strong brand recognition in transplant diagnostics
- Comprehensive product portfolio
- Established relationships with transplant centers
- Proprietary technology platform
- Large and growing customer base
Weaknesses
- High operating expenses
- Dependence on reimbursement approvals
- Competition from larger diagnostic companies
- Litigation risk
Opportunities
- Expanding into new transplant areas (e.g., lung, liver)
- Developing new diagnostic tests
- Acquiring complementary technologies
- Expanding internationally
- Increasing awareness of non-invasive testing options
Threats
- Changes in reimbursement policies
- Increased competition
- Technological obsolescence
- Negative clinical trial results
- Economic downturn
Competitors and Market Share
Key Competitors
- NVTA
- TMO
Competitive Landscape
CareDx faces competition from larger diagnostic companies and smaller, more specialized players. Its competitive advantages include its comprehensive product portfolio, strong brand recognition, and established relationships with transplant centers. Disadvantages include its high operating expenses and dependence on reimbursement approvals.
Major Acquisitions
OTTR
- Year: 2021
- Acquisition Price (USD millions): 160
- Strategic Rationale: Expand CareDx's digital transplant solutions and improve patient management.
Growth Trajectory and Initiatives
Historical Growth: CareDx has historically experienced strong revenue growth due to the increasing adoption of its transplant monitoring solutions. However, profitability has been challenged by high operating expenses.
Future Projections: Future growth projections depend on analyst estimates, which can be found from investment banks and financial research firms. Growth is expected to continue as the company expands its product portfolio and market reach.
Recent Initiatives: Recent initiatives include expanding into new transplant areas, developing new diagnostic tests, and investing in digital healthcare solutions.
Summary
CareDx is a leading transplant diagnostics company with a strong position in the kidney transplant monitoring market. Its revenue growth is impressive, but profitability is a concern. The company should focus on managing expenses and expanding into new markets to capitalize on its opportunities and mitigate risks. CareDx has a very strong customer base due to its customer support. The litigation from Natera is a major concern.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The data may not be fully up-to-date. Market share data are estimates and can vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CareDx Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2014-07-17 | President, CEO & Director Mr. John Walter Hanna Jr. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 644 | Website https://caredx.com |
Full time employees 644 | Website https://caredx.com | ||
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.